Allegion PLC vs Amphastar Pharmaceuticals Inc — how do they compare? Allegion PLC trades at $164.91 (market cap $14.32B), while Amphastar Pharmaceuticals Inc trades at $19.83 (market cap $868.62M). The key difference: Allegion PLC is far larger — about 16.5× Amphastar Pharmaceuticals Inc's market cap, and Allegion PLC pays a 1.26% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALLE | AMPH | |
|---|---|---|
Market Cap | $14.32B | $868.62M |
Sector | Industrials | Health |
52-Week High | $179.77 | $30.81 |
52-Week Low | $125.65 | $16.87 |
Enterprise Value | $16.03B | $1.27B |
Dividend Yield | 1.26% | — |
Signals from Pluang's Aura AI — not financial advice
Allegion (ALLE) trades at $165.53, down 2.02% today, near its consensus price target of $156. The stock shows bullish technical momentum with strong moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust Q2 2026 results with EPS of $2.40 beating estimates and revenue growth of nearly 13% year-over-year, driven by strength in its Americas segment. It maintains solid profitability with a net income margin of 15.36% and ROE of 33.73%.
The outlook is positive, supported by raised full-year guidance and institutional buying, but risks include high valuation multiples and reliance on Americas market growth. Analyst sentiment is mixed with a 'Hold' consensus, indicating cautious optimism amid strong operational performance.
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
Trailing returns across standard periods
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →